RT @DaveGennert: Dr. Maus showcased her stellar work with @StefanieBailey_ in @BCD_AACR finding dispensability of IFNg in #CARTcell respons…
RT @DaveGennert: Dr. Maus showcased her stellar work with @StefanieBailey_ in @BCD_AACR finding dispensability of IFNg in #CARTcell respons…
RT @DaveGennert: Dr. Maus showcased her stellar work with @StefanieBailey_ in @BCD_AACR finding dispensability of IFNg in #CARTcell respons…
Dr. Maus showcased her stellar work with @StefanieBailey_ in @BCD_AACR finding dispensability of IFNg in #CARTcell response > now being taken to trials: https://t.co/bAnbRxgUbN 2/2 #AACRbcd24 #immunotherapy https://t.co/Zv5aGlEiZY
RT @BCD_AACR: Read the paper from the BCD Award for Outstanding Journal Article winners, @MarcelaMaus et al. Blockade or Deletion of IFNγ R…
Read the paper from the BCD Award for Outstanding Journal Article winners, @MarcelaMaus et al. Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising #CARTcell Function in Hematologic Malignancies. https://t.co/WspzZiTkqU @MGHCance
Read the paper from the Blood Cancer Discovery Award for Outstanding Journal Article winners, @MarcelaMaus et al. Blockade or Deletion of IFNγReduces Macrophage Activation without Compromising #CARTcell Function in #HematologicMalignancies. https://t.co/W
RT @BCD_AACR: Attending #ICML2023 #17ICML? Follow up today's session on #CARTcell therapies with work from @MarcelaMaus and colleagues— Blo…
Attending #ICML2023 #17ICML? Follow up today's session on #CARTcell therapies with work from @MarcelaMaus and colleagues— Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T cell Function in #HematologicMalignancies. https
RT @SRBailey32: We’re so grateful that our paper on IFNg in CAR-T toxicity and efficacy was selected for this award. If you haven’t read it…
RT @SRBailey32: We’re so grateful that our paper on IFNg in CAR-T toxicity and efficacy was selected for this award. If you haven’t read it…
RT @SRBailey32: We’re so grateful that our paper on IFNg in CAR-T toxicity and efficacy was selected for this award. If you haven’t read it…
We’re so grateful that our paper on IFNg in CAR-T toxicity and efficacy was selected for this award. If you haven’t read it yet, go check it out!
RT @BCD_AACR: Read the paper from Blood Cancer Discovery Award for Outstanding Journal Article winners, Maus and colleagues— Blockade or De…
Read the paper from Blood Cancer Discovery Award for Outstanding Journal Article winners, Maus and colleagues— Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising #CARTcell Function in #HematologicMalignancies. https://t.co/Wspz
Read the paper from the Blood Cancer Discovery Award for Outstanding Journal Article winners, @MarcelaMaus et al— Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising #CARTcell Function in Hematologic Malignancies. https://t.co/W
Read the paper from the Blood Cancer Discovery Award for Outstanding Journal Article winners, @MarcelaMaus et al.— Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising #CARTcell Function in Hematologic Malignancies. https://t.co/
The article I presented for journal club yesterday (link below) investigating effects of IFNg on CAR-T efficacy and CRS in Hematologic Malignancies. Give it a read! @SRBailey32 @MarcelaMaus Link: https://t.co/YglBRiBLgb
RT @_TanyaBondar_: Is #CARTcell killing dependent on IFNg pathway, YES/NO? @MarcelaMaus lab has both answers. NO for hematologic cancers, a…
RT @_TanyaBondar_: Is #CARTcell killing dependent on IFNg pathway, YES/NO? @MarcelaMaus lab has both answers. NO for hematologic cancers, a…
Is #CARTcell killing dependent on IFNg pathway, YES/NO? @MarcelaMaus lab has both answers. NO for hematologic cancers, as first reported in their @BCD_AACR paper: https://t.co/HaRFANVU93; and YES for solid tumors, @nature reports this week.
RT @DaveGennert: @BCD_AACR Scientific Editor Marcela Maus shares recent results published in BCD showing IFNg-/- CD19-CAR Ts have no reduct…
RT @DaveGennert: @BCD_AACR Scientific Editor Marcela Maus shares recent results published in BCD showing IFNg-/- CD19-CAR Ts have no reduct…
RT @DaveGennert: @BCD_AACR Scientific Editor Marcela Maus shares recent results published in BCD showing IFNg-/- CD19-CAR Ts have no reduct…
@BCD_AACR Scientific Editor Marcela Maus shares recent results published in BCD showing IFNg-/- CD19-CAR Ts have no reduction in efficacy at #AACR22 #CART symposium. @SRBailey32 https://t.co/vp4t8Uvjbx https://t.co/vAXFaT6BOv
Getting ready for the #AACR22 plenary on Cellular Immunotherapy trials, with Blood Cancer Discovery Scientific Editor @MarcelaMaus? Check out her recent article on blocking IFNg in #CART cell therapy: https://t.co/qBIjgCvcNN https://t.co/ROfLnTr8Rl
Featured on the cover of this month’s Blood Cancer Discovery: Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising #CART cell Function in Hematologic Malignancies by Bailey, @MarcelaMaus et al. https://t.co/nnhbdibg1d @CHOPCancer
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies https://t.co/fKGd8YpFjn
#ICYMI: Blockade or deletion of IFNg reduces macrophage activation without compromising #CART function in hematologic malignancies by Bailey, @MarcelaMaus et al. https://t.co/G7sah5v4VQ @harvardmed https://t.co/b7P1hyKBS4
From the March issue: Blockade or deletion of IFNg reduces macrophage activation without compromising #CART function in hematologic malignancies by Bailey, @MarcelaMaus et al. https://t.co/ggI8GTXGVB @harvardmed https://t.co/JS9gvbA6RJ
Check out the paper featured on the cover of this month’s Blood Cancer Discovery: Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising #CART cell Function in Hematologic Malignancies by Bailey, @MarcelaMaus et al. https://t.co/Cq
RT @skyhigh0707: もう一つ紹介 CARTから放出されるIFNγは、マクロファージを活性化させるけれど、少なくとも血液腫瘍では、抗腫瘍効果にあまり関与してないかもしれない🤔 #週末はCART論文を読む時間です https://t.co/LEU7ORpySA
もう一つ紹介 CARTから放出されるIFNγは、マクロファージを活性化させるけれど、少なくとも血液腫瘍では、抗腫瘍効果にあまり関与してないかもしれない🤔 #週末はCART論文を読む時間です https://t.co/LEU7ORpySA
RT @BCD_AACR: Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignanci…
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies by @MarcelaMaus, Stefanie R. Bailey, and colleagues @harvardmed. https://t.co/CZUcejf6Ct https://t.co/lkSYtLGtg8
Update: the group of @MarcelaMaus published on IFN several months after I posted that tweet thread. https://t.co/deJxIeHFno #CARTcells https://t.co/9b3zez8uLG
#ICYMI: Blockade or deletion of IFNg reduces macrophage activation without compromising CAR-T function in hematologic malignancies by @MarcelaMaus, Stefanie R. Bailey and colleagues @harvardmed. https://t.co/9Na1Wk0HKN https://t.co/0wV18D90tc
RT @kasperMoelgaard: Blocking #CAR #TCell IFNg production does not interfere with anti-tumor reactivity but can reduce cytokines related to…
RT @kasperMoelgaard: Blocking #CAR #TCell IFNg production does not interfere with anti-tumor reactivity but can reduce cytokines related to…
Blocking #CAR #TCell IFNg production does not interfere with anti-tumor reactivity but can reduce cytokines related toxicities via reduced macrophage activation. In @BCD_AACR by Maus Group https://t.co/XphqBu1kMY
Blockade or deletion of IFNg reduces macrophage activation without compromising CAR-T function in hematologic malignancies #lymphoma #lymsm https://t.co/J24rn3EWyK
Great read new year! Stef Bailey @SRBailey32 in @MarcelaMaus is illuminating new ideas in IO space. Blockade/deletion of IFNg reduces macrophage activation w/o compromising CAR-T function in hematologic malignancies | Blood Cancer Discovery https://t.c
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
I can hear @adamnarloch salivating
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @BCD_AACR: Just published #OnlineFirst: Blockade or deletion of IFNg reduces macrophage activation without compromising CAR-T function i…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
RT @SRBailey32: Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispe…
Thought IFNg was required for CAR-T therapy? Think again! Check out our paper @BCD_AACR showing that not only is IFNg dispensable for effective CAR-T therapy, but its blockade can potentially mitigate clinical toxicities. @MarcelaMaus https://t.co/yEjXq4MT
RT @BCD_AACR: Just published #OnlineFirst: Blockade or deletion of IFNg reduces macrophage activation without compromising CAR-T function i…
331 #CancerImmunology Blockade or deletion of #IFNg reduces #macrophage activation without compromising #CAR-T function in #hematologic #malignancies https://t.co/lDe3WrXmVr
discussed now live at #ASH21
RT @MichaelDJain: Looking forward to reading this paper - startling result that IFNgamma is not needed for CAR T. A lot of the problems wit…
RT @_TanyaBondar_: Check out this work presented at #ASH21 by @SRBailey32 poster 1723 and by @MarcelaMaus talk at CAR-T Cell Therapies for…
RT @_TanyaBondar_: Check out this work presented at #ASH21 by @SRBailey32 poster 1723 and by @MarcelaMaus talk at CAR-T Cell Therapies for…
.@SRBailey32 and @BCD_AACR Scientific Editor @MarcelaMaus present poster 1723 at #ASH21 on Blocking IFNy in CAR-T Reduces Checkpoint Inhibitors and Cell-Mediated Toxicity. Read the full manuscript, now online: https://t.co/iiPMgayXJV @harvardmed #CARTcell
RT @_TanyaBondar_: Check out this work presented at #ASH21 by @SRBailey32 poster 1723 and by @MarcelaMaus talk at CAR-T Cell Therapies for…
RT @_TanyaBondar_: Check out this work presented at #ASH21 by @SRBailey32 poster 1723 and by @MarcelaMaus talk at CAR-T Cell Therapies for…
RT @_TanyaBondar_: Check out this work presented at #ASH21 by @SRBailey32 poster 1723 and by @MarcelaMaus talk at CAR-T Cell Therapies for…
RT @_TanyaBondar_: Check out this work presented at #ASH21 by @SRBailey32 poster 1723 and by @MarcelaMaus talk at CAR-T Cell Therapies for…
RT @MichaelDJain: Looking forward to reading this paper - startling result that IFNgamma is not needed for CAR T. A lot of the problems wit…
RT @MichaelDJain: Looking forward to reading this paper - startling result that IFNgamma is not needed for CAR T. A lot of the problems wit…
Looking forward to reading this paper - startling result that IFNgamma is not needed for CAR T. A lot of the problems with car t seem to stem from tumor driven inflammation so finding ways to block inflammation while retaining car function is important.
RT @Chrystal_Paulos: Must read alert. Exceptional body of work by Drs. Stefanie Bailey @SRBailey32 and Marcela Maus @MarcelaMaus on the un…
Must read alert. Exceptional body of work by Drs. Stefanie Bailey @SRBailey32 and Marcela Maus @MarcelaMaus on the unexpected biology of IFN-gamma on macrophages and CAR T cells in hematological diseases published in #BloodCancerDiscovery.
RT @_TanyaBondar_: Check out this work presented at #ASH21 by @SRBailey32 poster 1723 and by @MarcelaMaus talk at CAR-T Cell Therapies for…
My sister, y'all! 👏👏👏 I can't say I understand it fully, but I do know that this is some newly-published, groundbreaking cancer research and her name is at the top. So proud! ❤
RT @_TanyaBondar_: Check out this work presented at #ASH21 by @SRBailey32 poster 1723 and by @MarcelaMaus talk at CAR-T Cell Therapies for…
RT @_TanyaBondar_: Check out this work presented at #ASH21 by @SRBailey32 poster 1723 and by @MarcelaMaus talk at CAR-T Cell Therapies for…
RT @BCD_AACR: Just published #OnlineFirst: Blockade or deletion of IFNg reduces macrophage activation without compromising CAR-T function i…
RT @BCD_AACR: Just published #OnlineFirst: Blockade or deletion of IFNg reduces macrophage activation without compromising CAR-T function i…
RT @_TanyaBondar_: Check out this work presented at #ASH21 by @SRBailey32 poster 1723 and by @MarcelaMaus talk at CAR-T Cell Therapies for…
Check out this work presented at #ASH21 by @SRBailey32 poster 1723 and by @MarcelaMaus talk at CAR-T Cell Therapies for Hematologic Malignancies session. And read the accompanying In Focus by Shannon Maude, @GruppSteve and colleagues @CHOPCancerCnt https:
Just published #OnlineFirst: Blockade or deletion of IFNg reduces macrophage activation without compromising CAR-T function in hematologic malignancies. https://t.co/Jd1pcklkeE @SRBailey32 @MarcelaMaus @harvardmed #CARTcell #immunotherapy https://t.co/RP92